Breaking News Instant updates and real-time market news.

AMPH

Amphastar

$19.72

-0.1 (-0.50%)

, CVS

CVS Health

$65.55

0.06 (0.09%)

06:02
01/03/19
01/03
06:02
01/03/19
06:02

Amphastar announces launch of Primatene MIST to nationwide retail pharmacies

Pharmaceuticals (AMPH) announced that Primatene MIST has been launched. Primatene MIST is an epinephrine inhalation aerosol bronchodilator suspension, which is the only FDA-approved metered dose inhaler for asthma in the over-the-counter market in the United States. Primatene MIST is now available nationwide at Walgreens (WBA) stores and online at Walgreens and CVS (CVS). It will also be available nationwide at CVS stores by mid-January. The company is currently building additional inventory to provide Primatene MIST to more pharmacy chains and big box retail stores in the coming months.

AMPH

Amphastar

$19.72

-0.1 (-0.50%)

CVS

CVS Health

$65.55

0.06 (0.09%)

WBA

Walgreens Boots Alliance

$68.03

-0.31 (-0.45%)

  • 14

    Jan

AMPH Amphastar
$19.72

-0.1 (-0.50%)

06/19/18
WELS
06/19/18
NO CHANGE
WELS
Outperform
Amphastar generic Isuprel has $10M-$25M sales potential, says Wells Fargo
After Amphastar (AMPH) announced that the FDA approved its therapeutically equivalent generic of Valeant's (VRX) Isuprel, Wells Fargo analyst David Maris said he will discuss this with management when he meets them later today but his preliminary estimate is that this generic has a sales opportunity of $10M-$25M. Maris has an Outperform rating on Amphastar shares.
07/20/18
WELS
07/20/18
NO CHANGE
Target $23
WELS
Outperform
Wells Fargo positive on Amphastar after review of new Drug Master Files
Wells Fargo analyst David Maris says his review of new Drug Master Files added to the FDA's database in Q2 indicates that Amphastar Nanjing Pharmaceuticals (AMPH) filed a DMF for insulin aspart, the active ingredient in Novo Nordisk's (NVO) blockbuster diabetes therapy NovoLog. The NovoLog franchise had U.S. sales of $6.7B in 2017 while the original NovoLog product totaled $2.4B, Maris tells investors in a research note titled "DMF Dig Warrants Excitement." Amphastar confirmed the DMF filing to Maris and said it relates to the finished product pipeline, but would not comment on what specific branded product the filing targets. The insulin aspart DMF filing is from Amphastar's facility in Nanjing, China, which indicates this facility, not the company's plant in France, will be working on the NovoLog generic, Maris writes. The analyst likes Amphastar's focus on "difficult to develop generics and selected brands" and thinks the company as the potential to post "excellent growth" over a multiyear period. Maris keeps an Outperform rating on the shares with a $23 price target
08/09/18
WELS
08/09/18
NO CHANGE
Target $26
WELS
Outperform
Amphastar shares 'about the future,' says Wells Fargo
Wells Fargo analyst David Maris noted that Amphastar reported Q2 revenues that topped his estimate, but adjusted EPS that missed his and the consensus view. However, he does not view the miss as meaningful, as the lower than expected EPS was mainly due to spending on the pipeline and he believes Amphastar "shares are not about the current, but about the future." Maris, who thinks Amphastar could become a "much larger company" depending on key approvals over the next several years, keeps an Outperform rating on the shares with a price target of $26.
11/08/18
WELS
11/08/18
NO CHANGE
Target $26
WELS
Outperform
Amphastar inhaler approval could add $4-$6 per share, says Wells Fargo
Wells Fargo analyst David Maris points out that Amphastar Pharmaceuticals' Primatene Mist is the only FDA approved asthma inhaler available without a prescription in the United States, and used for the temporary relief of mild symptoms of intermittent asthma in people ages 12 and above. Primatene Mist could have peak sales over $65M, Maris tells investors in a research note. Given Amphstar's 2018 sales base is approximately $265M, the approval "could be transformative" for the company, says Maris. He believes the approval could add at least $210M to $280M in value to Amphastar, or $4 to $6 per share. Maris has an Outperform rating on the stock with a $26 price target. Amphastar in morning trading is up 9%, or $1.72, to $20.97.
CVS CVS Health
$65.55

0.06 (0.09%)

12/11/18
LEER
12/11/18
NO CHANGE
Target $100
LEER
Outperform
CVS Health assumed with an Outperform at Leerink
Leerink analyst Ana Gupte assumed coverage of CVS Health (CVS) with an Outperform rating and $100 price target. The analyst views the recently raised synergy guidance as having upside with earlier pull-through in 2019 despite the headwind from divestiture of Aetna (AET) Part D lives. Pricing and underwriting remain firm in 2019 based on her MEDACorp fully insured employer broker survey and she is comfortable on stable Commercial margins for the Aetna book. Further, Gupte sees the PBM business as being oversold as it is synergistically integrated with Aetna's MCO book over time into a full-service captive offering. Retail headwinds from e-commerce look largely priced into consensus estimates while multiples have compressed on fears of Amazon's (AMZN) entry into pharmacy, she contends.
12/14/18
GSCO
12/14/18
DOWNGRADE
Target $68
GSCO
Sell
Goldman downgrades Walgreens to Sell with $68 target, sees downside in 2019
Goldman Sachs analyst Robert Jones downgraded Walgreens Boots Alliance (WBA) to Sell from Neutral and lowered his price target for the shares to $68 from $73. The analyst says he struggles to make a "compelling fundamental case" for the Americas Healthcare Services Supply Chain heading into 2019 as "issues facing core growth drivers do not seem to be abating." Jones sees limited "core" growth for the large-cap names amid persisting sales and margin pressures and as drug pricing remains a regulatory focus. He downgrades Walgreens to Sell saying challenges in its retail pharmacy business "have intensified, forcing the company to search for other avenues of growth." Jones also keeps a Neutral rating on CVS Health (CVS) and Sell rating on Rite Aid (RAD).
12/18/18
LEHM
12/18/18
INITIATION
Target $91
LEHM
Overweight
CVS Health initiated with an Overweight at Barclays
Barclays analyst Steve Valiquette started CVS Health with an Overweight rating and $91 price target. The analyst views the acquisition of Aetna as well-timed and believes it will offset the company's slower growth in retail and pharmacy benefits.
12/18/18
LEHM
12/18/18
INITIATION
Target $91
LEHM
Overweight
Barclays starts CVS Health at Overweight after 'transformational' merger
Barclays analyst Steve Valiquette initiated coverage CVS Health with an Overweight rating and $91 price target. The analyst views the company's acquisition of Aetna as "well-timed" and "transformational." The good news for CVS is that Aetna has substantial leverage to the organic growth of the Medicare Advantage market, Valiquette tells investors in a research note. He projects 15% Medicare Advantage membership for Aetna in both 2019 and 2020. Further, for the combined company, Valiquette believes the $750M-plus in projected synergies by year two "should be more than achievable." The 2019 guidance in February "will be a clearing event for the stock," says the analyst.
WBA Walgreens Boots Alliance
$68.03

-0.31 (-0.45%)

12/14/18
12/14/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Walgreens Boots Alliance (WBA) downgraded to Sell from Neutral at Goldman Sachs with analyst Robert Jones saying he struggles to make a "compelling fundamental case" for the Americas Healthcare Services Supply Chain heading into 2019 as "issues facing core growth drivers do not seem to be abating." 2. Cisco (CSCO) downgraded to Neutral from Buy at Nomura Instinet with analyst Jeffrey Kvaal saying strengthening information technology spending, an innovation-led refresh cycle, and a rising software mix have lifted Cisco's multiple and its shares to post-recession highs. 3. Universal Health (UHS) downgraded to Sell from Neutral at Goldman Sachs with analyst Stephen Tanal saying a "healthy" macro environment helps acute hospitals' commercial mix, but behavioral health providers like Universal Health over-index to Medicaid and Medicare, "leaving them less exposed to the supportive backdrop." 4. Beacon Roofing (BECN) downgraded to Neutral from Outperform at Wedbush with analyst Jay McCanless saying that yesterday's investor day did not provide any new catalysts to raise EPS estimates or price target. 5. Kaman (KAMN) downgraded to Underweight from Neutral at JPMorgan with analyst Seth Seifman saying he values the stock at 14 times his 2020 earnings per share estimate of $4.05 while adding 15c for potentially accretive M&A, given the company's balance sheet capacity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/19/18
WOLF
12/19/18
INITIATION
WOLF
Peer Perform
Walgreens Boots Alliance assumed with a Peer Perform at Wolfe Research
12/20/18
LOOP
12/20/18
NO CHANGE
LOOP
Walgreens retains constructive guidance after mixed Q1, says Loop
Loop Capital analyst Andrew Wolf reiterated a Buy rating and $82 price target on Walgreens Boots Alliance after the company reported mixed Q1 earnings results that saw EPS beat the consensus due to aggressive share repurchases. The analyst noted that Walgreens retained "constructive" FY19 EPS guidance as "management continues to anticipate operating results will strengthen in the back half of FY19 as low-margin FEP business cycles." Wolf was also positive on the company's new 3-year $1B cost saving program that will be phased in with accelerating benefits.
12/27/18
GSCO
12/27/18
NO CHANGE
GSCO
Goldman sees potential for softer macro to weigh on U.K. dental, vet spending
Goldman Sachs analyst Nathan Rich said several recent data points, including consumer spending data and Walgreens Boots Alliance's (WBA) results, suggest a more challenging environment for U.K. consumers. Given this, he sees potential for the softer U.K. macro backdrop to weigh on spending for dental and vet services. Rich noted that Patterson (PDCO) generates the highest percentage of revenue in the U.K. among dental names he covers, at 11%, adding that Align Technology (ALGN), Henry Schein (HSIC) and Dentsply Sirona (XRAY) each have about 5% exposure on average.

TODAY'S FREE FLY STORIES

04:05
11/20/19
11/20
04:05
11/20/19
04:05
General news
FX Action: The Canadian dollar has come under notable pressure »

FX Action: The Canadian…

03:35
11/20/19
11/20
03:35
11/20/19
03:35
General news
FX Update: The dollar and yen have firmed up »

FX Update: The dollar and…

01:45
11/20/19
11/20
01:45
11/20/19
01:45
General news
Asian Market Update: »

Asian Market Update: JGB…

01:35
11/20/19
11/20
01:35
11/20/19
01:35
General news
Japan exports slumped 9.2% y/y in October, »

Japan exports slumped…

ESYJY

easyJet

$0.00

(0.00%)

20:35
11/19/19
11/19
20:35
11/19/19
20:35
Initiation
easyJet initiated at Goldman Sachs »

easyJet initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSEX

Middlesex Water

$62.07

1.5 (2.48%)

20:31
11/19/19
11/19
20:31
11/19/19
20:31
Syndicate
Middlesex Water 661K share Spot Secondary priced at $60.50 »

Baird is acting as lead…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

DLAKY

Lufthansa

$0.00

(0.00%)

20:29
11/19/19
11/19
20:29
11/19/19
20:29
Initiation
Lufthansa initiated at Goldman Sachs »

Lufthansa initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$110.86

0.27 (0.24%)

, LOW

Lowe's

$113.41

-1.62 (-1.41%)

20:25
11/19/19
11/19
20:25
11/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TGT

Target

$110.86

0.27 (0.24%)

LOW

Lowe's

$113.41

-1.62 (-1.41%)

NTES

NetEase

$288.77

-1.33 (-0.46%)

CPRT

Copart

$86.33

0.32 (0.37%)

LB

L Brands

$17.19

-0.67 (-3.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

ICAGY

IAG

$0.00

(0.00%)

20:23
11/19/19
11/19
20:23
11/19/19
20:23
Initiation
IAG initiated at Goldman Sachs »

IAG initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RYAAY

Ryanair

$86.27

0.52 (0.61%)

20:20
11/19/19
11/19
20:20
11/19/19
20:20
Initiation
Ryanair initiated at Goldman Sachs »

Ryanair initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXFR

Luxfer

$17.57

0.16 (0.92%)

20:11
11/19/19
11/19
20:11
11/19/19
20:11
Initiation
Luxfer initiated at B. Riley FBR »

Luxfer initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VAL

Valaris

$3.69

-0.515 (-12.26%)

20:09
11/19/19
11/19
20:09
11/19/19
20:09
Initiation
Valaris initiated at Deutsche Bank »

Valaris initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIG

Transocean

$4.66

-0.16 (-3.32%)

20:03
11/19/19
11/19
20:03
11/19/19
20:03
Initiation
Transocean initiated at Deutsche Bank »

Transocean initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$19.29

-0.24 (-1.23%)

19:58
11/19/19
11/19
19:58
11/19/19
19:58
Initiation
TechnipFMC initiated at Deutsche Bank »

TechnipFMC initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLB

Schlumberger

$34.31

-0.36 (-1.04%)

19:53
11/19/19
11/19
19:53
11/19/19
19:53
Initiation
Schlumberger initiated at Deutsche Bank »

Schlumberger initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTEN

Patterson-UTI

$8.49

-0.095 (-1.11%)

19:45
11/19/19
11/19
19:45
11/19/19
19:45
Initiation
Patterson-UTI initiated at Deutsche Bank »

Patterson-UTI initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAFE

Safehold

$34.59

-1.33 (-3.70%)

19:38
11/19/19
11/19
19:38
11/19/19
19:38
Syndicate
Safehold 3M share Secondary priced at $34.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 20

    Nov

HP

Helmerich & Payne

$38.39

-0.45 (-1.16%)

19:36
11/19/19
11/19
19:36
11/19/19
19:36
Initiation
Helmerich & Payne initiated at Deutsche Bank »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$19.89

-0.26 (-1.29%)

19:31
11/19/19
11/19
19:31
11/19/19
19:31
Initiation
Halliburton initiated at Deutsche Bank »

Halliburton initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

BKR

Baker Hughes

$22.01

-0.155 (-0.70%)

19:24
11/19/19
11/19
19:24
11/19/19
19:24
Initiation
Baker Hughes initiated at Deutsche Bank »

Baker Hughes initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHAT

Phathom Pharmaceuticals

$24.79

-0.09 (-0.36%)

19:23
11/19/19
11/19
19:23
11/19/19
19:23
Initiation
Phathom Pharmaceuticals initiated at Evercore ISI »

Phathom Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHW

Sherwin-Williams

$584.48

-1.13 (-0.19%)

19:20
11/19/19
11/19
19:20
11/19/19
19:20
Downgrade
Sherwin-Williams rating change at Edward Jones »

Sherwin-Williams…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$311.95

-0.06 (-0.02%)

, SPX

S&P 500

$0.00

(0.00%)

19:17
11/19/19
11/19
19:17
11/19/19
19:17
Periodicals
Commerce Sec Ross says China trade talks still work in progress, Bloomberg says »

U.S. Commerce Secretary…

SPY

SPDR S&P 500 ETF Trust

$311.95

-0.06 (-0.02%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRY

Berry Petroleum

$8.90

-2.405 (-21.27%)

19:10
11/19/19
11/19
19:10
11/19/19
19:10
Downgrade
Berry Petroleum rating change at KeyBanc »

Berry Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NYMT

New York Mortgage

$6.25

0.015 (0.24%)

19:05
11/19/19
11/19
19:05
11/19/19
19:05
Syndicate
New York Mortgage 25M share Spot Secondary priced at $6.10 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.